Bank of New York Mellon Corp Grows Stake in Perspective Therapeutics, Inc. (NYSE:CATX)

Bank of New York Mellon Corp raised its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 3.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 143,469 shares of the company’s stock after purchasing an additional 4,693 shares during the period. Bank of New York Mellon Corp owned about 0.21% of Perspective Therapeutics worth $458,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. FMR LLC increased its holdings in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the period. State Street Corp increased its holdings in shares of Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after acquiring an additional 1,192,812 shares during the period. Janus Henderson Group PLC raised its position in shares of Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after acquiring an additional 355,685 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Perspective Therapeutics by 221.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after purchasing an additional 298,778 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Perspective Therapeutics by 12.5% during the third quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock valued at $15,546,000 after purchasing an additional 129,654 shares in the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on CATX. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 19th. Scotiabank assumed coverage on Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective for the company. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Finally, Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Wednesday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $14.44.

Perspective Therapeutics Trading Up 1.3 %

Shares of Perspective Therapeutics stock opened at $2.30 on Friday. Perspective Therapeutics, Inc. has a 52 week low of $2.22 and a 52 week high of $19.05. The firm’s 50 day moving average is $2.96 and its two-hundred day moving average is $6.51.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.